These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 19434850)

  • 1. An investigation into the influence of counterion on the properties of some amorphous organic salts.
    Towler CS; Li T; Wikström H; Remick DM; Sanchez-Felix MV; Taylor LS
    Mol Pharm; 2008; 5(6):946-55. PubMed ID: 19434850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the counterion on the solubility and physicochemical properties of salts of carboxylic acid drugs.
    David SE; Timmins P; Conway BR
    Drug Dev Ind Pharm; 2012 Jan; 38(1):93-103. PubMed ID: 22118222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of counterions on the properties of amorphous atorvastatin salts.
    Sonje VM; Kumar L; Puri V; Kohli G; Kaushal AM; Bansal AK
    Eur J Pharm Sci; 2011 Nov; 44(4):462-70. PubMed ID: 21907794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Examination of Water Vapor Sorption by Multicomponent Crystalline and Amorphous Solids and Its Effects on Their Solid-State Properties.
    Newman A; Zografi G
    J Pharm Sci; 2019 Mar; 108(3):1061-1080. PubMed ID: 30391302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of relationships between solid-state properties, counterion, and developability of pharmaceutical salts.
    Guerrieri P; Rumondor AC; Li T; Taylor LS
    AAPS PharmSciTech; 2010 Sep; 11(3):1212-22. PubMed ID: 20680707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the glass-forming ability of active pharmaceutical ingredients for designing supersaturating dosage forms.
    Kawakami K; Usui T; Hattori M
    J Pharm Sci; 2012 Sep; 101(9):3239-48. PubMed ID: 22531946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating the moisture sorption behavior of amorphous sucrose using a dynamic humidity generating instrument.
    Yu X; Kappes SM; Bello-Perez LA; Schmidt SJ
    J Food Sci; 2008 Jan; 73(1):E25-35. PubMed ID: 18211350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Water-solid interactions. III. Effect of glass transition temperature, Tg, and processing on tensile strength of compacts of lactose and lactose/polyvinyl pyrrolidone.
    Stubberud L; Arwidsson HG; Hjortsberg V; Graffner C
    Pharm Dev Technol; 1996 Jul; 1(2):195-204. PubMed ID: 9552346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of aqueous content in small scale salt screening--improving hit rate for weakly basic, low solubility drugs.
    Tarsa PB; Towler CS; Woollam G; Berghausen J
    Eur J Pharm Sci; 2010 Sep; 41(1):23-30. PubMed ID: 20553863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a counterion on the glass transition temperature (T(g)') during lyophilization of ganciclovir salt forms.
    Kumar L; Baheti A; Bansal AK
    Mol Pharm; 2011 Feb; 8(1):309-14. PubMed ID: 21133416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel approach for analyzing glass-transition temperature vs. composition patterns: application to pharmaceutical compound+polymer systems.
    Kalogeras IM
    Eur J Pharm Sci; 2011 Apr; 42(5):470-83. PubMed ID: 21324354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database.
    Paulekuhn GS; Dressman JB; Saal C
    J Med Chem; 2007 Dec; 50(26):6665-72. PubMed ID: 18052022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of pharmaceutical salts and cocrystals to address the issue of poor solubility.
    Elder DP; Holm R; Diego HL
    Int J Pharm; 2013 Aug; 453(1):88-100. PubMed ID: 23182973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transformation of acidic poorly water soluble drugs into ionic liquids.
    Balk A; Wiest J; Widmer T; Galli B; Holzgrabe U; Meinel L
    Eur J Pharm Biopharm; 2015 Aug; 94():73-82. PubMed ID: 25976317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applicability of the one-step DVS method for the determination of amorphous amounts for further different hydrophilic and hydrophobic drugs.
    Müller T; Scherließ R; Schiewe J; Smal R; Weiler C; Steckel H
    Eur J Pharm Biopharm; 2015 Aug; 94():333-41. PubMed ID: 26079523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solubility of crystalline organic compounds in high and low molecular weight amorphous matrices above and below the glass transition by zero enthalpy extrapolation.
    Amharar Y; Curtin V; Gallagher KH; Healy AM
    Int J Pharm; 2014 Sep; 472(1-2):241-7. PubMed ID: 24968139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of salt screening methodologies.
    Fernández Casares A; Nap WM; Ten Figás G; Huizenga P; Groot R; Hoffmann M
    J Pharm Pharmacol; 2015 Jun; 67(6):812-22. PubMed ID: 25683791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative physical, mechanical and crystallographic properties of a series of gemfibrozil salts.
    David SE; Ramirez M; Timmins P; Conway BR
    J Pharm Pharmacol; 2010 Nov; 62(11):1519-25. PubMed ID: 21039537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solid molecular dispersions of poorly water-soluble drugs in poly(2-hydroxyethyl methacrylate) hydrogels.
    Zahedi P; Lee PI
    Eur J Pharm Biopharm; 2007 Mar; 65(3):320-8. PubMed ID: 17182231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.